Taken together, these results demonstrated that the use of TrkA kinase-specific inhibitors may provide a new therapeutic strategy for targeted treatment not only for NTRK1 fusion-driven lung adenocarcinoma and sarcoma but also for colon cancer. This evidence concerns the gene NTRK1 and sarcoma.